OCREVUS ZUNOVO
@ocrevus-hcp.com
OCREVUS ZUNOVO® (ocrelizumab & hyaluronidase-ocsq) treats relapsing & primary progressive multiple sclerosis (RMS & PPMS). See full safety for more information.
OCREVUS ZUNOVO's Company Logos
OCREVUS ZUNOVO's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#FFC40C
Supernova
255, 196, 12
45, 100, 52
0, 23, 95, 0
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#333333
Mine Shaft
51, 51, 51
0, 0, 20
0, 0, 0, 80
About OCREVUS ZUNOVO
OCREVUS® (ocrelizumab) is a pioneering treatment option specifically designed for patients dealing with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This FDA-approved therapy is recognized as the #1 prescribed disease-modifying therapy (DMT) in the United States, attributed to its extensive clinical trial data and over a decade of safety experience, treating more than 300,000 patients globally.
OCREVUS is administered via intravenous infusion, typically requiring three treatments in the first year, with subsequent doses every six months. Its flexible treatment plan includes a two-hour infusion option, making it a convenient choice for patients embarking on their MS journey.
The brand’s commitment to patient care extends beyond medication, offering a wealth of resources including clinical education, financial support, and patient navigators. For individuals seeking comprehensive management of multiple sclerosis, OCREVUS delivers both effective treatment and dedicated support, reinforcing its standing as a leader in MS care.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
Related Brands
Tags
Multiple sclerosis disease-modifying treatment
Ocrelizumab
CD20-directed therapy
Subcutaneous injection for MS
Intravenous infusion for MS
